Coronavirus Variants Spur FDA To Write New Guidance For COVID-19 Test Developers
The US agency’s immediately-in-effect guidance document – released on 22 February – explains how makers of COVID-19 diagnostics can assess whether their tests are impacted by mutations of the virus.
You may also be interested in...
The US FDA said this week that the DTPM COVID-19 RT-PCR Test made by Tide Laboratories LLC could give erroneous readings because of the latest coronavirus variant.
US FDA device center director Jeff Shuren said on 22 July that the agency is worried about the Delta variant, but is taking the steps necessary to ensure that coronavirus diagnostics give accurate readings.
The US FDA says it’s concerned that virus mutations could lead to false results with certain COVID-19 tests and lists tests it has found are prone to lower sensitivity, based on the agency’s own analysis.